12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Denosumab regulatory update

Daiichi Sankyo said it submitted a regulatory application in Japan for denosumab to treat osteoporosis. The human mAb targeting receptor activator of NF-kappa...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >